Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 1, 1997, Pages 34-44

  Miller, Jeffrey S ^a,c   Tessmer Tuck, Jennifer ^a   Pierson, Bryce A ^a   Weisdorf, Daniel ^a   McGlave, Philip ^a   Blazar, Bruce R ^a   Katsanis, Emmanuel ^a   Verfaillie, Catherine ^a   Lebkowski, Jane ^b   Radford Jr , James ^a   Burns, Linda J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b RPR Gencell   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST TUMOR; CELL CULTURE; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG SELF ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MIDDLE AGED; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; SECRETION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; MALE; MIDDLE AGED; SELF ADMINISTRATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0031113474     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Antman K, Ayash L, Anthony E, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose chemotherapy. J Clin Oncol 10:102, 1992.
2. Williams SF, Gilewski T, Mick R, Bitran JD: High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743, 1992.
3. Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M, Hromas R, Cornetta K, Einhorn LE: Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13:2025, 1995.
4. Weisdorf DJ, Verfaillie CM, Miller WJ, Blazar BR, Perry E, Shu XO, Daniels K, Hannan P, Ramsay NKC, Kersey JH, McGlave PB: Autologous bone marrow versus peripheral blood stem cell transplantation for lymphoid malignancies: A prospective, comparative trial. American J Hematology, in press.
5. Weisdorf DJ, Miller WJ, McGlave PB, Lasky LC, Ramsay NKC, Kersey J, Hurd D: Autologous bone marrow transplantation for progressive non-Hodgkins lymphoma. Bone Marrow Transplantation 8:135, 1991.
6. Burns LJ, Daniels KA, McGlave PB, Miller WJ, Ramsay NK, Kersey JH, Weisdorf DJ: Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Bone Marrow Transplantation 16:13, 1995.
7. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517, 1992.
8. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P: Large-scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplantation 14:555, 1994.
9. Baume DM, Caligiuri MA, Manley TJ, Daley JF, Ritz J: Differential expression of CD8a and CD8b associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cell Immunol 131:352, 1990.
10. Miller JS, Oelkers S, Verfaillie C, McGlave PB: Role of monocytes in the expansion of human activated natural killer cells. Blood 80:2221, 1992.
11. Pierson BA, Miller JS: CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli which recruit clonogenic NK, and exhibit decreased proliferation on a per cell basis. Blood 88:2279, 1996.
12. Lotzova E, Savary CA, Herberman RB: Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Research 11:1059, 1987.
13. Lotzova E: Role of natural killer cells in defense against leukemia: Therapeutic considerations. Nat Immun Cell Growth Regul 7:170, 1988.
14. Whiteside TL, Ernstoff MS, Nair S, Kirkwood JM, Herberman RB: In vitro generation and in vivo effects of adherent lymphokine-activated killer cells and IL-2 in patients with solid tumors., in Schmidt RE (ed): Natural Killer Cells: Biology and Clinical Significance. Basel, Switzerland, Karger, 293, 1990.
15. Schwarz RE, Felgar RE, Hiserodt JC: Successful adoptive immunotherapy of established lung and liver metastases with highly purified IL-2 activated natural killer cells (A-LAK cells), in Schmidt R (ed): Natural Killer Cells: Biology and Clinical Significance. Basel, Switzerland, Karger, 303, 1990.
16. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Kendall SA, Ritz J: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J of Clin Invest 91:123, 1993.
17. Schmidt RE: Natural killer cells: Biology and clinical application: In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats. Basel, Karger, 303, 1990.
18. Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S, Lineham W, Robertson C, Lee R, Rubin J, Siepp C, Simpson C, White D: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889, 1987.
19. Verfaillie C, Kay N, Miller W, McGlave PB: Diminished A-LAK cytotoxicity and proliferation accompanies disease progression in chronic myelogenous leukemia. Blood 76:401, 1990.
20. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningbam I, Castro-Malaspinia H, O'Reilly RJ, Keever CA: Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250, 1990.
21. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortim MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991.
22. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995.
23. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malapina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995.
24. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050, 1994.
25. Ruvollo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G, Jones R, Hes A: Cyclosporine-induced autologous graft versus host disease: Assessment of cytolytic effector mechanisms and the v-beta T-cell receptor repertoire. Transplantation Proceedings 27:1363, 1995.
26. Weisdorf D, Katsanis E, Verfaillie C, Ramsay NK, Haake R, Garrison L, Blazar BR: Interleukin-1 alpha administered after autologous transplantation: A phase I/II clinical trial. Blood 84:2044, 1994.
27. Gingrich RD, Burns LJ, Wen BD, Clamon G: A phase II study of high-dose chemotherapy with marrow stem cell support in advanced breast cancer. Proc ASCO 10:67 (abstract), 1991.
28. Cervantes F, Shi XO, McGlave PB, Ramsay NKC, Miller WJ, Kersey JH, Weisdorf DJ: Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplantation 16:387, 1995.
29. Pierson BA, McGlave PB, Hu WS, Miller JS: Natural killer cell proliferation is dependent on human serum (HS) and markedly increased utilizing an enriched basal medium. Journal of Hematotherapy 4:149, 1994.
30. Weisdorf DJ, Anderson PM, Blazar BR, Uckun FM, Kersey JH, Ramsay NK: Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - a phase I study. Transplantation 55:61, 1993.
31. Sato K, Yamazaki K, Shizume K, Yamakawa Y, Satoh T, Demura H, Obara T, Fujimoto Y, Aiba M: Pathogenesis of autoimmune hypothyroidism induced by lymphokine-activated killer (LAK) cell therapy: In vitro inhibition of human thyroid function by interleukin-2 in the presence of autologous intrathyroidal lymphocytes. Thyroid 3:179, 1993.
32. Koizumi S, Mashio Y, Mizuo H, Matsuda A, Matsuya K, Mizumoto H, Ikota A, Beniko M, Iriuda Y: Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. Internal Medicine 34:58, 1995.
33. Gooding R, Riches P, Dadian G, Moore J, Gore M: Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. British Journal of Cancer 72:452, 1995.
34. Peest D, Leo R, Blocke S, Hein R, Stannat-Kiessling S, Tschechne B, Fett W, Harms P, Hoffmann L, Bartl R: Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. British Journal of Haematology 89:328, 1995.
35. Dilloo D, Laws HJ, Hanenber gH, Korholz D, Nurnberger W, Burdach SE: Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. Experimental Hematology 22:1081, 1994.
36. Warren HS, Kinnear BF, Phillips JH, Lamer LL: Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol 154:5144, 1995.
37. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J: Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity. J Clin Oncol 9:2110, 1991.
38. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB: Nosocomial sepsis associated with interleukin-2. Annals of Internal Medicine 112:102, 1990.
39. Vlasveld LT, Rodenhuis S, Rutgers E, Dubbelman AC, Hilton AM, Batchelor D, Rankin EM: Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. European Journal of Surgical Oncology 20:122, 1994.
40. Klempner MS, Noring R, Mier JW, Atkins MB: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Eng J Med 322:959, 1990.
41. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA: Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clinical Cancer Research 2:669, 1996.
42. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 87:2476, 1996.
43. Vivier E, Morin P, O'Brien C, Druker B, Schlossman SF, Anderson P: Tyrosine phosphorylation of the FcγRIII(CD16): ζ complex in human natural killer cells. Induction by antibody dependent cytotoxicity but not by natural killing. J Immunol 146:206, 1991